| Lead Manager/ | # of | Price Range | Dollar | SCOOP | ||
| New Filings (Proposed Symbol) | Joint-Lead Managers | Shares | Low | High | Volume | Ratings |
| inVentiv Group Holdings (TBA) | Credit Suisse/ Morgan Stanley/ Goldman Sachs/ Jefferies | $100.00 | n.a. | |||
| Viamet Pharmaceuticals (VMET) | Morgan Stanley/ Goldman Sachs | $100.00 | n.a. | |||
| Yintech Investment Holdings Limited (YIN) | Jefferies | $80.00 | n.a. | |||
| n.a. (not available) | ||||||
| TBA (to be announced) | ||||||
| Postponed | ||||||
| None | ||||||
| Withdrawn | ||||||
| None | ||||||
| New Terms | ||||||
| American Renal Associates Holdings (ARA) | BofA Merrill Lynch/ Barclays/ Goldman Sachs/ Wells Fargo Securities/ SunTrust Robinson Humphrey Leerink Partners | 7.50 | $20.00 | $23.00 | $161.25 | n.a. |
| MGM Growth Properties LLC (MGP) | BofA Merrill Lynch/ J.P. Morgan/ Morgan Stanley/ Evercore ISI/ Barclays/ Citigroup/ Deutsche Bank Securities | 50.00 | $18.00 | $21.00 | $975.00 | n.a. |
| n.a. (not available) | ||||||
| IPOs Priced | Lead | Shares | Amount | Offer | Close | % |
| Week of April 4, 2016 | Manager(s) | Offered | Raised | Price | 4/8/16 | Change |
| Aeglea BioTherapeutics (AGLE) | UBS Investment Bank/ BMO Capital Markets/ Wells Fargo Securities | 5.00 | $50.00 | $10.00 | $11.99 | 19.90% |
